Skip to main content
. 2010 May 10;107(24):10791–10798. doi: 10.1073/pnas.0914076107

Fig. 1.

Fig. 1.

An IGF-1R inhibitor does not significantly impair tumor growth in RIP1-Tag2 mice. (A and B) RIP1-Tag2; Rag-KO mice were treated in a 3-week intervention trial with the A12 anti–IGF-1R mAb or control antibody from 10 to 13 weeks of age (n = 13, control antibody treated mice; n = 15, A12 treated mice). Effects of A12 on tumor burden (A) and tumor number (B; *P = 0.04). (C and D) RIP1-Tag2 mice of tumor-bearing age (13 to 14 weeks) were treated in a short-term, 4-day trial with A12 or control antibody to assess effects on tumor cell apoptosis (C) as measured by TUNEL staining (*P = 0.01) and on proliferation (D) as measured by BrdU incorporation. Results represent values calculated from 15 to 20 tumor sections from three mice per group. Mean values plus SEM indicated; two-tailed, unpaired t test (with Welch correction for C and D) for statistical significance. (E) RIP1-Tag2 mice were treated with 1 mg A12 or control antibody and analyzed 6 h after injection. Pools of seven to eight tumors from three to four mice per group were analyzed by Western blotting for protein levels of IGF-1R and phosphorylated AKT (pAKT) and MEK (pMEK); blots were stripped and reprobed with antibodies to total AKT and MEK1/2 for protein load control.